Automated cell analysis with Haemorasis can help diagnose blood disorders

Scientists from the German Cancer Research Center (DKFZ) and the Cambridge Stem Cell Institute have developed an AI system that recognizes and characterizes white and red blood cells in microscopic images of blood samples. The algorithm can help physicians diagnose blood disorders and is available as an open source method for research purposes.

Blood disorders are often characterized by altered numbers and aberrant shapes of red and white blood cells. To diagnose the diseases, physicians classically examine blood smears on a slide under a microscope. This type of diagnosis is straightforward, but evaluation by experienced experts is difficult because the changes are sometimes very inconspicuous and affect only a few of the tens of thousands of visible cells.

Due to these difficulties, the differentiation of diseases is not always easy. For example, the visible changes in the blood of patients with myelodysplastic syndrome (MDS), an early form of leukemia, often resemble those of much more harmless forms of anemia. The definitive diagnosis of MDS therefore requires additional more invasive procedures, such as analysis of bone marrow biopsies and molecular genetic testing.

"To support specialists in these difficult diagnoses, we have developed a computer-based system that automatically recognizes and characterizes white and red blood cells from peripheral blood," explains Moritz Gerstung of DKFZ. Gerstung and colleagues first trained the algorithm, called Haemorasis, to recognize the cell morphology of more than half a million white blood cells as well as many millions of red blood cells from more than 300 individuals with different blood disorders (various anemias and forms of MDS).

The algorithm is able to detect the shape and number of tens of thousands of blood cells in a microscopic image of the blood. This complements human capabilities, which are typically more focused on detail."

Moritz Gerstung of DKFZ

Using the trained knowledge, Haemorasis can now suggest diagnoses of blood disorders and even distinguish genetic subtypes of the diseases. In addition, the algorithm also reveals concrete correlations between certain cell morphologies and diseases, which are often difficult to find because of the large number of cells involved.

Haemorasis has already been tested on three independent groups of patients to demonstrate that the system also works in other test centers and blood count scanner systems "We have now demonstrated for the first time that computer-assisted analysis of blood images is possible and can contribute to initial diagnosis," explains Gerstung. Haemorasis is designed to facilitate diagnostics in hematology and can help make a more accurate initial diagnosis of blood disorders. This is important for identifying those patients who require more invasive testing, such as bone marrow punctures or genetic analysis.

"Automated cell analysis with Haemorasis could complement routine diagnosis of blood disorders in the future. So far, the algorithm has only been trained on specific diseases - but we still see great potential in this approach," Gerstung says. He stresses that further studies are needed to identify potential limitations of the method.

Source:
Journal reference:

de Almeida, J. G., et al. (2023) Computational analysis of peripheral blood smears detects disease-associated cytomorphologies. Nature Communications. doi.org/10.1038/s41467-023-39676-y.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Next-generation cell-penetrating antibodies could transform cancer treatment